

QP Code: 103521

Reg. No: .....

**M.Ch (Gynaecological Oncology) Degree Supplementary  
Examinations June 2024**

**Paper III – Gynaecologic Oncology Part II (Medical and Radiation Oncology  
related to Gynaecologic Oncology)**

**Time: 3 hrs**

**Max marks: 100**

- *Answer all questions to the point neatly and legibly • Do not leave any blank pages between answers • Indicate the question number correctly for the answer in the margin space*
- *Answer all parts of a single question together • Leave sufficient space between answers*
- *Draw table/diagrams/flow charts wherever necessary*

**Essay: (20)**

1. How has the randomized trial by Landoni et al (1997) and the subsequent publication with 20 year follow up data influenced the management of early carcinoma cervix. Discuss critically the trial design, participant selection criteria, interventions and outcomes and the toxicities observed in this trial with respect to the above. (5+15)

**Short essays: (8x10=80)**

2. What is Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC). Describe its role in palliative treatment of recurrent ovarian cancer. (3+7)
3. Describe the role of paclitaxel in first line treatment of serous ovarian cancer. What are the common side effects. (7+3)
4. How will you follow up a patient of hydatidiform mole after surgical evacuation who did not need any adjuvant chemotherapy.
5. What is the role of brachytherapy in the treatment of cervical cancer.
6. Describe the circumstances where adjuvant radiotherapy is used after surgery for vulval cancer.
7. Justify the role of chemotherapy as adjuvant treatment in endometrial serous carcinoma with pelvic and para-aortic lymph node metastasis.
8. Describe adjuvant treatment and follow up after surgery in a patient with endometrial stromal sarcoma with peritoneal metastasis.
9. Discuss the role of bevacizumab in the treatment of cervical cancer.

\*\*\*\*\*